Nirmatrelvir/Ritonavir Reduces COVID-19-Related Hospitalization, All-Cause Death Among Patients At High Risk For Severe Disease, Study Finds

Infectious Disease Advisor (1/3, Nye) reported, “Nirmatrelvir/ritonavir (Paxlovid) reduced COVID-19-related hospitalization and all-cause death, as well as the duration of COVID-19 symptoms and utilization of health care resources among patients at high risk for severe disease, according to study findings.” The researchers said, “NMV/r not only reduces the risk of hospitalization or death in symptomatic, high-risk adults with mild to moderate COVID-19 but also consistently demonstrated efficacy in alpha-protected secondary and supportive efficacy endpoints.” The findings were published in Clinical Infectious Diseases.